Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
Randomized parallel group study comparing the renal safety of Captisol-Enabled™ Iohexol (CE-Iohexol) Injection and Omnipaque™ (Iohexol) Injection in patients with impaired renal function undergoing coronary angiography.
Description: Evaluate the incidence of CI-AKI in patients with impaired renal function undergoing coronary angiography, from baseline to any blood draw within 7 days following intravascular administration of CE-iohexol compared with Omnipaque (iohexol).
Measure: Incidence of contrast-induced acute kidney injury (CI-AKI) Time: 7 daysDescription: Compare image quality of coronary angiography in patients administered CE-iohexol versus iohexol as assessed quantitatively using a Visual Analog Scale (VAS).
Measure: Image quality Time: Day 1Description: Evaluate the changes in SCr in patients administered CE-iohexol versus iohexol.
Measure: Change in serum creatinine (SCr) Time: 7 daysDescription: Evaluate the proportion of patients exhibiting an increase in SCr following intravascular administration of CE-iohexol compared with iohexol.
Measure: Proportion of patients exhibiting an increase in SCr Time: 7 daysDescription: The number of patients with adverse events (AE) and severe adverse events will be assessed and graded according to Common Terminology Criteria for Adverse Events (CTCAE) v 4.0. Monitoring for Major Adverse Cardiac and Renal Events (MARCEs) will be part of the AE assessment.
Measure: Incidence of Adverse Events Time: 30 daysDescription: Evaluate the changes in serum cystatin C in patients administered CE-iohexol versus iohexol.
Measure: Change in serum cystatin C Time: 7 daysDescription: Compare image quality of coronary angiography in patients administered CE-iohexol versus iohexol as assessed by the investigator using qualitative methods.
Measure: Investigator Assessed Image Quality Time: Day 1Description: Evaluate the change in blood and urine biomarkers of renal injury from baseline to peak at 48 hours in patients administered CE-iohexol versus iohexol. Biomarkers may include neutrophil gelatinase-associated lipocalin, liver-type fatty acid binding protein, and kidney injury molecule-1.
Measure: Change in novel biomarkers of renal injury Time: 7 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports